The Chase Group Executive Search Logo
“Committed to Excellence in Life Sciences Executive Search”

Blog I

Developing ‘Knock-Your-Socks-Off Antibodies’ That Improve the Lives of Cancer Patients

December 12, 2019
The pipeline of rare disease drugs in development at Ionis Pharmaceuticals has grown significantly in the last five years. And, with a robust pipeline combined with a commercialization strategy, including complex partnerships involving complicated deal structures, financial leadership roles are key to managing the process and bringing life-changing therapies to market. When Ionis needs to fill critical leadership roles, The Chase Group delivers outstanding people who are committed to the mission and the culture. Continue Reading →

Immunology Institute: Expanding the Computational Biology Team to Directly Impact Human Health

November 27, 2019
The Allen Institute for Immunology recently launched a retained search, led by The Chase Group, dedicated to building the computational biology team at the Institute… Continue Reading →

Eisai, Inc. Cuts to the Chase for Their Recruiting Expertise in Global Medical Affairs, Oncology

September 9, 2019
A boutique firm working exclusively in life sciences, The Chase Group, with 25+ years’ executive search experience, can identify and deliver the highest quality executives… Continue Reading →

A New Era Begins with Head of Pathology Placement at Genmab

August 28, 2019
Dr. Suzana Couto joins Genmab Pharmaceuticals as Head of Pathology, leading the pathology teams located in Utrecht, Netherlands, and Princeton, New Jersey. This international biotechnology… Continue Reading →

Through Partnership with The Chase Group, Aeglea BioTherapeutics Continues Building Rare Disease Clinical Development Leadership Team

August 12, 2019
The Chase Group is honored to continue our partnership with Aeglea BioTherapeutics as we work to build their Rare Disease Clinical Development Leadership team. As… Continue Reading →

Data Science Leadership Team Set to Expand with The Chase Group/Genmab Partnership

August 6, 2019
The Chase Group is proud to be partnering with Genmab, a publicly traded, international, biotechnology company with the goal of transforming oncology research by discovering… Continue Reading →

Eli Lilly Partnership Continues in Medical Affairs Oncology

June 28, 2019
Eli Lilly continues to partner with The Chase Group to build the Medical Affairs Oncology team for their Cyramza® portfolio. The Chase Group is currently… Continue Reading →

Genmab Selects The Chase Group to Build Data Science Team

April 1, 2019
Genmab A/S specializes in the creation and development of antibody therapeutics for the treatment of cancer. When highly specialized talent is needed, Genmab relies on… Continue Reading →

Eli Lilly Welcomes New Vice President, Immuno-Oncology Global & US Medical Affairs

April 1, 2019
The Chase Group is pleased to announce the placement of the Vice President, Immuno-Oncology Global & US Medical Affairs for Eli Lilly. The successful candidate… Continue Reading →

Oncology Teams Set to Grow with Eli Lilly and The Chase Group Partnership

November 26, 2018
Lilly Oncology is known for its exciting pipeline across multiple tumor types and dedication to addressing the unmet needs of people living with cancer. Their… Continue Reading →
© Copyright 1993-2019 The Chase Group; All Rights Reserved.